ArticleScience signaling2012
Where EGF receptors transmit their signals.
Article in Science signaling, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance.Acta pharmacologica Sinica · 2026Review
- The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications.Signal transduction and targeted therapy · 2025Review
- Attenuation of IFITM proteins' antiviral activity through sequestration into intraluminal vesicles of late endosomes.Frontiers in immunology · 2025Article
- HB-EGF activates EGFR to induce reactive neural stem cells in the mouse hippocampus after seizures.Life science alliance · 2024Article
- Arf GTPase-Activating proteins ADAP1 and ARAP1 regulate incorporation of CD63 in multivesicular bodies.Biology open · 2024Article
- EGFR trafficking: effect of dimerization, dynamics, and mutation.Frontiers in oncology · 2023Review
- Neuregulin-1/ErbB4 upregulates acetylcholine receptors via Akt/mTOR/p70S6K: a study in a rat model of obstetric brachial plexus palsy andActa biochimica et biophysica Sinica · 2022Article
- Disabled 1 Is Part of a Signaling Pathway Activated by Epidermal Growth Factor Receptor.International journal of molecular sciences · 2021Article
- Quantitative proteomics reveals reduction of endocytic machinery components in gliomas.EBioMedicine · 2019Article
- Endosomal binding kinetics of Eps15 and Hrs specifically regulate the degradation of RTKs.Scientific reports · 2017Article
- Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- EGFR expression is associated with cytoplasmic staining of CXCR4 and predicts poor prognosis in triple-negative breast carcinomas.Oncology letters · 2017Article
- Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation.Biochemical and biophysical research communications · 2016Article
- Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival.Oncogene · 2016Article
- Image-based compound profiling reveals a dual inhibitor of tyrosine kinase and microtubule polymerization.Scientific reports · 2016Article
- CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells.Journal of translational medicine · 2016Article
- Cationic Polyamidoamine Dendrimers as Modulators of EGFR Signaling In Vitro and In Vivo.PloS one · 2015Article
- Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.The Journal of clinical investigation · 2014Article
- EGF receptor trafficking: consequences for signaling and cancer.Trends in cell biology · 2014Review
- Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors.Molecular cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Excessive signaling by receptor tyrosine kinases (RTKs) can cause cancer. What molecular mechanisms normally control RTK signaling? Are they defective in tumors? If so, should therapeutics be developed to restore particular regulatory pathways to cancer cells? These questions have been approached through mechanistic studies of a prototypical RTK, the epidermal growth factor receptor (EGFR). EGFR signaling is mediated and regulated by both signaling and trafficking effectors. The amplitude of receptor-proximal signals changes as EGFRs move along the degradative trafficking pathway from the cell surface, to endosomes, and into lysosomes. To optimize therapeutic suppression of receptor oncogenicity, it may be crucial to target EGFRs that are signaling from a specific site in the trafficking pathway. Research suggests that EGFRs at the plasma membrane produce the bulk of the global transcriptional response to EGF. EGFRs localized between the internalization and early endosome fusion stages of the pathway enrich the expression of transcripts associated with cancer. EGFRs at later trafficking checkpoints controlled by the endosomal sorting complex required for transport (ESCRT) complexes II and III do not contribute substantially to the EGFR-mediated transcriptional response. These results suggest that therapeutics targeting the receptors at the earliest stages of degradative trafficking might be most effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.